AstraZeneta China and Greenlee Pharmaceuticals announced a strategic partnership

AstraZene China becomes the exclusive licensed promoter of LipidCon capsules in Chinese mainlandJanuary 16, 2019, Shanghai, China - Today, AstraZenecon China announced an agreement with Green leaf pharmaceutical group to formally announce the exclusive promotion of Lipidcon capsule products in Chinese mainland. Green leaf pharmaceutical continues to hold assets and commercial sales rights of the drug, as well as registration permits, all intellectual property rights and other promotion rights. This is the first time that a large multinational pharmaceutical company has been granted the right to promote innovative chinese prescription drugs developed independently by Chinese pharmaceutical companies. In the context of the state's efforts to promote the implementation of the Outline of the Outline of the Development Strategy for Chinese Medicine, this will also help to upgrade the modernization level and international competitiveness of Chinese medicine, promote the upgrading of the Chinese medicine health industry, and is expected to help open up the international development path of Chinese medicine, so that high-quality local Traditional Chinese medicine benefits the vast number of patients.this partnership, AstraZene China will work closely with Greenlee Pharmaceuticals to give full play to the advantages of both sides, consolidate and expand the sales market for lipid kang capsule products, and bring more quality treatment solutions to patients. It is reported that Leaf Pharmaceuticals is committed to innovative drug research and development, production and marketing of international pharmaceutical companies. Its high-quality products are currently the only domestic clinical hard end to benefit, and has completed the United States FDA Phase II clinical research, recognized at home and abroad natural lipid drug brands. Based on the clear efficacy and safety of lipid reduction, hemolipid kang capsules have been recommended as first-line lipid management drugs by the Guidelines for the Prevention and Control of Blood Lipid Abnormality in Chinese Adults (revised in 2016) and included in the latest edition of China's National Basic Medical Insurance and Industrial Injury Insurance Drug Catalog and the National Essential Drugs Catalog.This partnership is another collaboration between AstraZeneca and Greenlee Pharmaceuticals, which will begin with 10 years, and take advantage of AstraZeneca's deep-ploughed cardiovascular business for many years, using its high-quality academic outreach capabilities and extensive commercial network to further expand the reach of lipid consum capsules in China for the benefit of more patients with cardiovascular diseases. The partnership will further enrich and improve AstraZeneia's cardiovascular product line, complement its blood lipid abnormalities and atherosclerosis product lines, and contribute to the long-term growth of AstraZeneta's China and cardiovascular businesses.On the basis of this cooperation, the two sides are discussing the space for further strategic cooperation in the United States, Europe and emerging markets, and look forward to accelerating the spread of lipid consum capsules to more countries and regions around the world, taking advantage of AstraZenecon's resources in the field of cardiovascular therapy. At present, in addition Chinese mainland, blood lipid capsules have been listed in Taiwan, Hong Kong, Singapore, Malaysia and other markets.25 years since it was established in China, AstraZeneta has been committed to a 'patient-centric' philosophy, focusing on the most pressing disease areas in China, finding and providing quality medical resources for patients. Cardiovascular is one of AstraZeneta's key business areas in China. We hope that in the future, we can bring more breadth and depth of coverage to lipid health, and can actually help more people with cardiovascular disease in China. Mr. Wang Lei, Executive Vice President of AstraZeneta Global, International Business and President of China, said, "AstraZenece will spare no effort to deepen cooperation with our local partners in China to promote high-quality and innovative medicines that benefit a wide range of patients." Today, we hope to take this cooperation as the cornerstone, the use of international pharmaceutical management concepts, the integration of the advantages of resources, promote the internationalization of domestic innovative drugs, and further promote high-quality traditional Chinese medicine to the world. Yang Rongbing, President ofGreen Leaf Pharmaceutical Group, is confident of this cooperation: "Blood lipid kang capsules are one of the core products independently developed by Green leaf Pharmaceuticals, and its fat-conditioning efficacy has been widely recognized by doctors and patients in long-term clinical applications." This strong joint with AstraZeneta will enable this trusted natural drug to reach more patients in need in China, and will accelerate the expansion of the development space of lipid consum capsules in various international markets, further strengthening the competitive advantage of green leaf pharmaceutical in the cardiovascular field.For this cooperation, the Chinese Academy of Sciences, the Chairman of the Chinese Cardiovascular Health Alliance, Professor Ge Zhubo also affirmed, he said: "Blood lipid kang is a natural lipid medicine, is one of the many Chinese authoritative guidelines recommended for the initial treatment of blood lipid abnormalities." It is expected that leading multinational pharmaceutical companies such as AstraZeneta will be able to spread more and better Chinese drugs globally for the benefit of more patients with blood lipid abnormalities. " about blood lipid kang capsules blood lipid kang capsules for the green leaf pharmaceutical group's products, is the use of modern process fermentation of special red music made of pure natural lipids. Hemolipid capsules have the effect of regulating abnormal blood lipids, which can reduce total cholesterol, triglycerides, LDL cholesterol and elevate HDL cholesterol, inhibit the formation of atherosclerotic plaques, protect endotrine cells in blood vessels, and inhibit lipid deposition in the liver.The product has been on the market for more than 20 years, including China Coronary Heart Disease Secondary Prevention Research (CCSPS) and other large-scale clinical evidence-based medical research has confirmed that: lipid health can inhibit cholesterol synthesis, and significantly reduce the total mortality rate of coronary heart disease patients, coronary heart disease mortality and cardiovascular event rate, less adverse reactions. The clinical results of hemolipid congener-congenerum-lying mebu also showed that the reduction of LDL-C after co-use could be significantly reduced by 45%, whether it was for single-use of lipid-health or in association with lyso-wheat cloth. In addition, lipid health contains a variety of beneficial ingredients can also work together to reduce fat and protect the cardiovascular system.About AstraZeneiaAstraZeneta is a science-focused global biopharmaceutical company focused on the development, production and marketing of prescription drugs, focusing on the three therapeutic areas of oncology, respiratory, and cardiovascular, kidney and metabolism. AstraZeneta operates in more than 100 countries, and innovative drugs benefit millions of patients worldwide. For more information, please visit http://www.scotsman.comRecess About AstraZenecom China Since entering China in 1993, AstraZeneta has adhered to the scientific supremacy, focusing on innovation to meet China's growing health needs, and achieving the grand vision of "pioneering and innovating for the benefit of patients and becoming China's most trusted healthcare partner". Headquartered in Shanghai, AstraZeneta has established production sites in Wuxi and Taizhou, as well as a Chinese logistics center in Wuxi. In China, AstraZenecom's focus is on the treatment areas most needed by patients in China, including respiratory, cardiovascular, metabolic, tumor, digestive and kidney diseases. In 2017, AstraZene cum's China Business Innovation Center landed in Wuxi to explore innovative, integrated, full-course management solutions for healthy IoT diagnosis and treatment. In the same year, AstraZeneta and Guo investment innovation joint venture set up Dizhe (Jiangsu) Pharmaceutical Co., Ltd. to accelerate the pace of local research and development of new drugs for the benefit of Chinese patients. (AstraZene
).